Risk factors for the coexistence of inflammatory bowel disease and nonalcoholic fatty liver disease: A Meta-analysis

Feng Gong; He Na; Mi Man; Li XuePing; Liu ManLing; Fan LiPing; Niu ChunYan

doi:10.3969/j.issn.1001-5256.2019.04.025

Volume 35 Issue 4

Apr. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(4): 835-839

PDF( 2509 KB)

Risk factors for the coexistence of inflammatory bowel disease and nonalcoholic fatty liver disease: A Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2019.04.025

Xi′an Medical University

Research funding:

Published Date: 2019-04-20

Abstract

Abstract

Objective To investigate whether glucocorticoids, anti-tumor necrosis factor ( anti-TNF) drugs, and a past history of surgical treatment of inflammatory bowel disease ( IBD) are the risk factors for the coexistence of IBD and nonalcoholic fatty liver disease ( NAFLD) . Methods PubMed, Embase, Cochrane Library, Wanfang Data, CNKI, and VIP were searched for clinical trials of the coexistence of IBD and NAFLD published up to October 2018. The articles included were summarized and quality assessment was performed according to inclusion and exclusion criteria. RevMan 5. 2 was used for data processing; the random effects model was used for data with heterogeneity, and the fixed effect model was used for data with homogeneity. Results A total of 7 articles were included, with 1645 patients.The meta-analysis showed that glucocorticoids might not be a risk factor for the coexistence of IBD and NAFLD ( odds ratio ( OR) = 1. 19, 95% confidence interval ( CI) : 0. 90-1. 57, P = 0. 23) ; anti-TNF drugs were not a risk factor for the coexistence of IBD and NAFLD ( OR = 0. 86, 95% CI: 0. 65-1. 13, P = 0. 27) ; a past history of surgical treatment of IBD was a risk factor for the coexistence of IBD and NAFLD ( OR = 1. 50, 95% CI: 1. 09-2. 05, P = 0. 01) . Conclusion Glucocorticoids and anti-TNF drugs for the treatment of IBD may not increase the incidence rate of the coexistence of IBD and NAFLD, while surgical treatment for IBD may increase this incidence rate.
- inflammatory bowel diseases,
- nonalcoholic fatty liver disease,
- risk factors,
- Meta-analysis

FullText(HTML)

References(24)

References

[1]YOUNOSSI ZM, BLISSETT D, BLISSETT R, et al.The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe[J].Hepatology, 2016, 64 (5) :1577-1586.

[2]BARGIGGIA S, MACONI G, ELLI M, et al.Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease:Study of 511 subjects at a single center[J].J Clin Gastroenterol, 2003, 36 (5) :417-420.

[3] BESSISSOW T, LE NH, ROLLET K, et al.Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease[J].Inflamm Bowel Dis, 2016, 22 (8) :1937-1944.

[4]CAPPELLO M, RANDAZZO C, BRAVATI, et al.Liver function test abnormalities in patients with inflammatory bowel diseases:A hospital-based survey[J].Clin Med Insights Gastroenterol, 2014, 7:25-31.

[5]CHANDRASHEKARAN V, SETH RK, DATTAROY D, et al.HMGB1-RAGE pathway drives peroxynitrite signaling-induced IBD-like inflammation in murine nonalcoholic fatty liver disease[J].Redox Biol, 2017, 13:8-19.

[6]BESSISSOW T, LE NH, ROLLET K, et al.Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease[J].Inflamm Bowel Dis, 2016, 22 (8) :1937-1944.

[7]BOSCH DE, YEH MM.Primary sclerosing cholangitis is protective against nonalcoholic fatty liver disease in inflammatory bowel disease[J].Hum Pathol, 2017, 69:55-62.

[8]GLASSNER K, MALATY HM, ABRAHAM BP.Epidemiology and risk factors of nonalcoholic fatty liver disease among patients with inflammatory bowel disease[J].Inflamm Bowel Dis, 2017, 23 (6) :998.

[9]SAGAMI S, UENO Y, TANAKA S, et al.Significance of nonalcoholic fatty liver disease in Crohn's disease:A retrospective cohort study[J].Hepatol Res, 2017, 47 (9) :872-881.

[10]SCHRDER T, SCHMIDT KJ, OLSEN V, et al.Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease under immunosuppressive treatment[J].Eur JGastroenterol Hepatol, 2015, 27 (6) :698-704.

[11]SOURIANARAYANANE A, GARG G, SMITH TH, et al.Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease[J].J Crohns Colitis, 2013, 7 (8) :e279-e285.

[12]SAROLI PC, RESTELLINI S, CHAO CY, et al.Screening for nonalcoholic fatty liver disease in inflammatory bowel diseases:A cohort study using transient elastography[J].Inflamm Bowel Dis, 2018.[Epub ahead of print]

[13]DOLINSKY VW, DOUGLAS DN, LEHNER R, et al.Regulation of the enzymes of hepatic microsomal triacylglycerol lipolysis and re-esterification by the glucocorticoid dexamethasone[J].Biochem J, 2004, 378 (3) :967-974.

[14]D'SOUZA AM, BEAUDRY JL, SZIGIATO AA, et al.Consumption of a high-fat diet rapidly exacerbates the development of fatty liver disease that occurs with chronically elevated glucocorticoids[J].Am J Physiol Gastrointest Liver Physiol, 2012, 302 (8) :850-863.

[15]HUBEL JM, SCHMIDT SA, MASON RA, et al.Influence of plasma cortisol and other laboratory parameters on nonalcoholic fatty liver disease[J].Horm Metab Res, 2015, 47 (7) :479-484.

[16]LAPUMNUAYPOL K, KANJANAHATTAKIJ N, PISARCIK D, et al.Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease:A meta-analysis[J].Eur JGastroenterol Hepatol, 2018, 30 (8) :854-860.

[17]RUIZ AG, CASAFONT F, CRESPO J, et al.Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients:Evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis[J].Obes Surg, 2007, 17 (10) :1374-1380.

[18]BARBUIO R, MILANSKI M, BERTOLO MB, et al.Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet[J].J Endocrinol, 2007, 194 (3) :539-550.

[19]KOCA SS, BAHCECIOGLU IH, POYRAZOGLU OK, et al.The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine-and choline-deficient diet[J].Inflammation, 2008, 31 (2) :91-98.

[20]YALCIN M, AKARSU M, CELIK A, et al.A comparison of the effects of infliximab, adalimumab, and pentoxifylline on rats with non-alcoholic steatohepatitis[J].Turk J Gastroenterol, 2014, 25 (Suppl 1) :167-175.

[21]ADAMS LA, ZEIN CO, ANGULO P, et al.A pilot trial of pentoxifylline in nonalcoholic steatohepatitis[J].Am J Gastroenterol, 2004, 99 (12) :2365-2368.

[22]ANGELICO M, DELLA GP.Review article:Hepatobiliary complications associated with total parenteral nutrition[J].Aliment Pharmacol Ther, 2000, 14 (Suppl 2) :54-57.

[23]FENG G, NIU CY.Advances in the treatment of nonalcoholic fatty liver disease[J].J Clin Hepatol, 2017, 33 (12) :2433-2438. (in Chinese) 冯巩, 牛春燕.非酒精性脂肪性肝病的治疗进展[J].临床肝胆病杂志, 2017, 33 (12) :2433-2438.

[24]NEUSCHWANDER-TETRI BA, LOOMBA R, SANYAL AJ, et al.Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT) :Amulticentre, randomised, placebo-controlled trial[J].Lancet, 2015, 385 (9972) :956-965.

Relative Articles

[1]	Zhiguo LI, Xun MA, Yongan YE, Xianzhao YANG. Regulatory effect of Kangxian Yiai Prescription in a rat model of precancerous lesions of liver cancer： A study based on the mTOR/HIF-1α/VEGF signaling pathway[J]. Journal of Clinical Hepatology, 2024, 40(10): 2049-2054. doi: 10.12449/JCH241019
[2]	Xing YANG, Shudi LI, Jiangkai LIU, Zhen WANG, Suling LI. Current research status of traditional Chinese medicine in the prevention and treatment of hepatocellular carcinoma by regulating the JAK/STAT signaling pathway[J]. Journal of Clinical Hepatology, 2023, 39(11): 2718-2729. doi: 10.3969/j.issn.1001-5256.2023.11.030
[3]	Rui SONG, Jing LI, Hongju YANG, Minyue LI, Jing YOU. Role of signal transducer and activator of transcription 1 in regulation of Treg/Th17 balance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(11): 2627-2631. doi: 10.3969/j.issn.1001-5256.2022.11.038
[4]	Hong XIANG, Fenglin HU, Xufeng TAO, Xin QI, Jinnan ZHANG, Dong SHANG. Artemisia capillaris Thunb. decoction exerts a protective effect on rats with severe acute pancreatitis by regulating the lncRNA PVT1/miRNA-30a-5p signaling pathway[J]. Journal of Clinical Hepatology, 2021, 37(1): 147-152. doi: 10.3969/j.issn.1001-5256.2021.01.029
[5]	Xuemei DING, Shilun WU, Wenbing SUN. Value of preoperative microRNA-192 in peripheral blood mononuclear cells in predicting microvascular invasion of solitary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1121-1125. doi: 10.3969/j.issn.1001-5256.2021.05.028
[6]	Xiuhong HUANG, Xiaoli XIE, Huiqing JIANG. Value of a microRNA risk score model in predicting the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1110-1115. doi: 10.3969/j.issn.1001-5256.2021.05.026
[7]	Zhihua ZUO, Chuyi ZENG, Yao JIANG, Hualin TAO, Yongcan GUO. Regulatory role of long non-coding RNAs in the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(7): 1704-1707. doi: 10.3969/j.issn.1001-5256.2021.07.048
[8]	LU NenYuan, ZHONG FangFei, DENG QingMei, YANG YanQi, ZHENG Yang, ZHAO TieJian, LIANG TianJian. Regulatory effect of long non-coding RNAs on liver fibrosis[J]. Journal of Clinical Hepatology, 2020, 36(12): 2811-2814. doi: 10.3969/j.issn.1001-5256.2020.12.035
[9]	HUANG Qing, LI JingTao, LIU YongGang, WEI HaiLiang, YAN ShuGuang, GUO YingJun, CHANG ZhanJie. Regulatory effect of mTOR pathway-mediated autophagy in liver injury[J]. Journal of Clinical Hepatology, 2020, 36(11): 2621-2625. doi: 10.3969/j.issn.1001-5256.2020.11.051
[10]	Wang ZeXin, Guan LiJun, Li JianMing, Wang ZhiChao, Xue MengRuo, Qin XiaoJun. Effect of targeted regulation of the Wnt2 gene by microRNA( microRNA-21) on the proliferation and migration of HepG2 hepatoma cells[J]. Journal of Clinical Hepatology, 2020, 36(4): 803-807. doi: 10.3969/j.issn.1001-5256.2020.04.019
[11]	Niu YaQian, Chang YuLing, Liu Fang, Zhao Chuan, Chen Che. Regulatory role of microRNA in aerobic glycolysis in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(9): 2082-2084. doi: 10.3969/j.issn.1001-5256.2019.09.044
[12]	Huang XiangJun, Zhang WenXing. Expression features and clinical significance of the microRNA-888 gene family in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(1): 119-122. doi: 10.3969/j.issn.1001-5256.2019.01.022
[13]	Zhao Jing, Yang XingWu, Li JingTao, Wang Qi, Wang Liang, Wang GuoTai. Construction and functional enrichment analysis of circRNA-miRNA-mRNA regulatory network for liver cancer based on high-throughput sequencing[J]. Journal of Clinical Hepatology, 2019, 35(8): 1740-1744. doi: 10.3969/j.issn.1001-5256.2019.08.018
[14]	Meng Jian, Du SongTao, Zhang JingGuang. Clinical effect of recombinant adenovirus containing thymidine kinase suicide gene in preventing postoperative recurrence of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(10): 1944-1948. doi: 10.3969/j.issn.1001-5256.2017.10.019
[15]	Zhang ChuanTao, Gu HaiYing, Huang Qun, Liu YeFang, Wang DeLi, Zheng ZhengLong, Hu Rong, Qiao WeiJuan. Molecular mechanism in the pathogenesis of mild chronic hepatitis B based on microRNA regulation[J]. Journal of Clinical Hepatology, 2016, 32(6): 1130-1134. doi: 10.3969/j.issn.1001-5256.2016.06.022
[16]	Cui XiangHua, Jia JiDong. Research advances in micro RNAs in regulating hepatitis C virus replication and antiviral therapy[J]. Journal of Clinical Hepatology, 2015, 31(5): 800-802. doi: 10.3969/j.issn.1001-5256.2015.05.042
[17]	Gou ZePeng, Wang DeSheng, Zhou Liang, Zhu PuLi, Zhang Yong, Sun Wei. The research progress of STAT3 on the regulation of hepatocellular carcinoma invasion and metastasis[J]. Journal of Clinical Hepatology, 2012, 28(4): 308-311.
[18]	Chen Peng, Zheng SuJun, Wang ShiMei, Zhang JianJun, Xing XinYue, Zhang Ying, Liu Mei, Duan ZhongPing. Selection of siRNA and construction of recombinant lentivirus expressing shRNA targeting rat Smad3 gene[J]. Journal of Clinical Hepatology, 2011, 27(5): 533-537.
[19]	Liu Mei, Zhang LiLi, Chen Ming, Pan XiuCheng, Li Li. The expression of suppressor of cytokine signaling-1 mRNA in the peripheral blood mononuclear cells of patients with chronic hepatitis B infection[J]. Journal of Clinical Hepatology, 2011, 27(5): 500-502.
[20]	Xu QingTian, Ji Ying, Du ShaoCai, Wang HuiMin, Li XinYue, Tao QiMin. Significance of comparing hepatitis C virus (HCV) RNA by polymerase chain reaction between at NS 5b region and 5’-noncoding region[J]. Journal of Clinical Hepatology, 2000, 16(4): 214-215.

Supplements(0)

Cited By

Cited by

Periodical cited type(8)

1.	蒋丽莎，马洪升. 日归手术——中国日间手术的升华. 华西医学. 2022(02): 161-164 .
2.	雷甜甜，梁鹏，马洪升，蒋丽莎. 四川大学华西医院日归手术管理实践. 广东医学. 2022(10): 1222-1228 .
3.	方宁波，陈伟力. 腹腔镜胆囊切除术日间手术围术期指标观察及患者延迟出院原因分析. 江西医药. 2022(10): 1524-1527 .
4.	刘力玮，郑亚民，刘东斌，王悦华，刘家峰，梁阔，江华，高崇崇，于志浩，徐大华. 日间腹腔镜胆囊切除术的可行性分析. 腹腔镜外科杂志. 2021(05): 359-362 .
5.	杨奕夫，黎柏峰，肖艳. 日间腹腔镜胆囊切除术质量控制的研究进展. 腹腔镜外科杂志. 2020(10): 796-798+800 .
6.	李航，赵礼金. 老年患者腹腔镜胆囊切除日间手术的安全性分析. 中国普通外科杂志. 2019(08): 1012-1017 .
7.	石鑫，秦琦瑜，刘维丽，胥静，王威. “三镜”联合治疗胆囊结石合并肝外胆管结石手术效果及安全性研究. 临床军医杂志. 2018(06): 710-712 .
8.	张少成，张亚辉，徐小梦. 年龄因素对上胆道疾病患者行腹腔镜胆囊切除术安全性的影响. 深圳中西医结合杂志. 2018(06): 184-186 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1446) PDF downloads(299)

Risk factors for the coexistence of inflammatory bowel disease and nonalcoholic fatty liver disease: A Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2019.04.025